Short-term modulation of the renin-angiotensin system does not alter plasma adrenomedullin concentration in humans.
OBJECTIVE
Adrenomedullin (AM) and proadrenomedullin N-terminal 20 peptide (PAMP) are novel hypotensive peptides produced from the same precursor. A relationship between AM and the renin-angiotensin-aldosterone (RAA) axis was reported in several studies, but the response of the above two peptides to short-term modulation of the RAA axis in humans is not yet clear. Here, we assessed the responses of AM and PAMP in patients with varying RAA system status, including renovascular hypertension (RVH) and primary aldosteronism (PA).


METHODS
Essential hypertension (EHT), RVH and PA patients were hospitalized and maintained on a standard diet (NaCl 10 g/day). The patients underwent a captopril (25 mg) loading test. A renin-secretion stimulating test (furosemide 1 mg/kg, i.v. +2 h of walking) and an ACTH loading test were performed for the PA patients. The plasma renin activity (PRA), plasma aldosterone concentration (PAC), and plasma AM and PAMP levels were monitored before and after the loadings.


RESULTS
In the basal state, significantly higher concentrations of AM and PAMP were shown in the RVH patients compared to the other groups. AM and PAMP were significantly correlated with PRA but not PAC in all patients. The AM and PAMP levels were not affected by the captopril loading with or without a hypotensive reaction. The AM and PAMP levels were increased only slightly despite the large increase in PAC induced in the PA patients by the renin-secretion stimulating and ACTH loading tests.


CONCLUSIONS
The responses of plasma AM and PAMP to a short-term modulation of the RAA system were relatively small, despite the correlations observed between PRA and AM or PAMP.
Kita
T
T
First Department of Internal Medicine, Miyazaki Medical College, Japan.
Kitamura
K
K
Kuwasako
K
K
Kawamoto
M
M
Eto
T
T
D000324:Adrenocorticotropic Hormone; D053607:Adrenomedullin; D000328:Adult; D000959:Antihypertensive Agents / Q000008:administration & dosage; D002216:Captopril / Q000008:administration & dosage; D005260:Female; D005665:Furosemide; D006801:Humans; D006929:Hyperaldosteronism / Q000097:blood / Q000503:physiopathology; D006973:Hypertension / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology; D006978:Hypertension, Renovascular / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000378:metabolism; D010455:Peptides / Q000097:blood*; D011506:Proteins / Q000378:metabolism; D012083:Renin / Q000378:metabolism; D012084:Renin-Angiotensin System / Q000187:drug effects* / Q000502:physiology*
D000959:Antihypertensive Agents; D010446:Peptide Fragments; D010455:Peptides; D011506:Proteins; D053607:Adrenomedullin; D005665:Furosemide; D000324:Adrenocorticotropic Hormone; D002216:Captopril; D012083:Renin